The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement
{{output}}
Sacituzumab govitecan (SG) is a therapeutic antibody-drug conjugate globally approved for the treatment of breast cancer. SG targets the trophoblast cell-surface antigen-2 (Trop2) at the surface of cancer cells to deliver the cytotoxic topoisomerase I inhibito... ...